← All candidates
34 insider filings on record.
34 filings on record.
DNLIDenali Therapeutics Inc.
NasdaqGS · Healthcare · $3.26B
$20.38
-3.96% · Sep 15
34 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 6 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.26B
Float
155.1M
97% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
903.9
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
29 more transactions on Pro →Context
Wall St
$33.93 avg target
+66.5% vs today · 15 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26−$0.69 act+$0.02
Q4 '25−$0.73 act+$0.02
Q3 '25−$0.74 act+$0.02
Q2 '25−$0.72 act+$0.02
Coverage
Denali to Sell Priority Review Voucher for $195M Cash BoostZacks · 06-19Pfizer CFO to step down; Denali sells a regulatory fast-passBioPharma Dive · 06-18What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech NamesInsider Monkey · 06-11Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff BezosInsider Monkey · 06-01
The file stays open
34 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice